| |
Centre for Policy on Ageing | |
 | |
|
| Judicial review of the Institute's guidance on the use of donepezil, rivastigmine, galantamine (review) and memantine for the treatment of Alzheimer's disease, NICE technology appraisal 111 | | Author(s) | Andrew Dillon |
| Corporate Author | National Institute for Health and Clinical Excellence - NICE |
| Publisher | National Institute for Health and Clinical Excellence, London, [August 2007] |
| Pages | 1 p |
| Source | National Institute for Health and Clinical Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. http://www.nice.org.uk |
| Keywords | Dementia ; Drugs ; Law reports ; Circulars. |
| Annotation | This circular letter from NICE's Chief Executive, Andrew Dillon, gives notification of the judicial review published on 10 August 2007, of the NICE technology appraisal 111. The judicial review ruled that donepezil, rivastigmine and galantamine continue to be recommended only for people with moderate Alzheimer's disease (AD). However, the judge ruled that NICE did breach its duties under the Disability Discrimination Act and the Race Relations Act by not offering specific advice regarding people with learning disabilities and people for whom English is not their first language in its technology appraisal guidance. This guidance will now be amended and available on their website on Friday 7 September 2007 and has force from that date; see (http://www.nice.org.uk/TA111). (KJ/RH). |
| Accession Number | CPA-070904520 B |
| Classmark | EA: LLD: 6PP: 6I * |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|